MME and chronic kidney disease: there have been several clinical studies examining the effects of enhancing NP signaling on progression of chronic kidney disease (CKD) using a drug combination that contained both the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan [78–80].